Titre
Kaposi sarcoma herpes virus antibody response and viremia following highly active antiretroviral therapy in the Swiss HIV Cohort study.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Sullivan, S.G.
Auteure/Auteur
Hirsch, H.H.
Auteure/Auteur
Franceschi, S.
Auteure/Auteur
Steffen, I.
Auteure/Auteur
Amari, E.B.
Auteure/Auteur
Mueller, N.J.
Auteure/Auteur
Magkouras, I.
Auteure/Auteur
Biggar, R.J.
Auteure/Auteur
Rickenbach, M.
Auteure/Auteur
Clifford, G.M.
Auteure/Auteur
Contributrices/contributeurs
Battegay, M.
Bernasconi, E.
Böni, J.
Bucher, HC.
Bürgisser, P.
Calmy, A.
Cavassini, M.
Dubs, R.
Egger, M.
Elzi, L.
Fischer, M.
Flepp, M.
Fontana, A.
Francioli, P.
Furrer, H.
Fux, CA.
Gorgievski, M.
Günthard, HF.
Hirsch, HH.
Hirschel, B.
Hösli, I.
Kahlert, C.
Kaiser, L.
Karrer, U.
Kind, C.
Klimkait, T.
Ledergerber, B.
Martinetti, G.
Martinez de Tejada, B.
Müller, N.
Nadal, D.
Paccaud, F.
Pantaleo, G.
Rauch, A.
Regenass, S.
Rickenbach, M.
Rudin, C.
Schmid, P.
Schultze, D.
Schöni-Affolter, F.
Schüpbach, J.
Speck, R.
Taffé, P.
Telenti, A.
Trkola, A.
Vernazza, P.
Weber, R.
Yerly, S.
Groupes de travail
Swiss HIV Cohort Study
Liens vers les personnes
Liens vers les unités
ISSN
1473-5571
Statut éditorial
Publié
Date de publication
2010
Volume
24
Numéro
14
Première page
2245
Dernière page/numéro d’article
2252
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Résumé
OBJECTIVE: To describe the effect of HAART on Kaposi sarcoma herpes virus (KSHV) antibody response and viremia among HIV-positive MSM.
DESIGN: A follow-up study of 272 HIV-positive MSM (including 22 with Kaposi sarcoma) who first initiated HAART between January 1996 and July 2004 in the Swiss HIV Cohort Study.
METHODS: For each individual, two serum samples, one at HAART initiation and another 24 months later, were tested for latent and lytic KSHV antibodies using immunofluorescence assays, and for KSHV viremia using PCR. Factors associated with changes in KSHV antibody titers and viremia were evaluated.
RESULTS: At HAART initiation, 69.1 and 75.0% of patients were seropositive to latent and lytic KSHV antibodies, respectively. Seropositivity was associated with the presence of Kaposi sarcoma, older age, lower CD8 cell count and higher CD4/CD8 ratio. Prevalence of KSHV viremia at HAART initiation was 6.4%, being significantly higher among patients with Kaposi sarcoma (35.0%), and those with HIV viral loads 100 000 copies/ml (11.7%) or higher. At 24-month follow-up, geometric mean titers (GMTs) among KSHV seropositive patients increased and antibody seroprevalence was higher. Having Kaposi sarcoma and/or CD4 cell counts less than 50 cells/microl at HAART initiation was associated both with higher probability for antibody titers to increase (including seroconversion) and larger increases in GMTs. Only one of 17 viremic patients at HAART initiation had viremia at 24-month follow-up.
CONCLUSION: HAART increases KSHV-specific humoral immune response and clearance of viremia among HIV-infected MSM, consistent with the dramatic protection offered by HAART against Kaposi sarcoma.
DESIGN: A follow-up study of 272 HIV-positive MSM (including 22 with Kaposi sarcoma) who first initiated HAART between January 1996 and July 2004 in the Swiss HIV Cohort Study.
METHODS: For each individual, two serum samples, one at HAART initiation and another 24 months later, were tested for latent and lytic KSHV antibodies using immunofluorescence assays, and for KSHV viremia using PCR. Factors associated with changes in KSHV antibody titers and viremia were evaluated.
RESULTS: At HAART initiation, 69.1 and 75.0% of patients were seropositive to latent and lytic KSHV antibodies, respectively. Seropositivity was associated with the presence of Kaposi sarcoma, older age, lower CD8 cell count and higher CD4/CD8 ratio. Prevalence of KSHV viremia at HAART initiation was 6.4%, being significantly higher among patients with Kaposi sarcoma (35.0%), and those with HIV viral loads 100 000 copies/ml (11.7%) or higher. At 24-month follow-up, geometric mean titers (GMTs) among KSHV seropositive patients increased and antibody seroprevalence was higher. Having Kaposi sarcoma and/or CD4 cell counts less than 50 cells/microl at HAART initiation was associated both with higher probability for antibody titers to increase (including seroconversion) and larger increases in GMTs. Only one of 17 viremic patients at HAART initiation had viremia at 24-month follow-up.
CONCLUSION: HAART increases KSHV-specific humoral immune response and clearance of viremia among HIV-infected MSM, consistent with the dramatic protection offered by HAART against Kaposi sarcoma.
Sujets
PID Serval
serval:BIB_0AF3C2377B57
PMID
Date de création
2010-12-29T15:43:17.519Z
Date de création dans IRIS
2025-05-20T18:04:38Z